The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Diseases

Background:

• Aggressively lowering low-density lipoprotein (LDL) cholesterol offers significant benefits in reducing atherosclerotic disease burden.
• Current lipid-lowering therapies often fall short of achieving recommended LDL cholesterol goals at standard doses.
• Combining effective statins with complementary agents or using higher doses are current strategies for enhanced LDL reduction.

Purpose of the Study:

• To evaluate the efficacy of rosuvastatin in achieving greater LDL cholesterol reductions compared to existing statins.
• To assess rosuvastatin's potential utility in managing hypercholesterolemia, particularly in patients with primary and familial forms.

Main Methods:

• Phase III clinical trials were conducted to compare rosuvastatin with other statins.
• Efficacy was measured by the degree of LDL cholesterol reduction in patients with hypercholesterolemia.

Main Results:

• Rosuvastatin demonstrated significantly greater LDL cholesterol reductions than atorvastatin, simvastatin, and pravastatin in primary hypercholesterolemia.
• In patients with familial hypercholesterolemia, rosuvastatin achieved significantly greater LDL reductions than the maximal dose of atorvastatin.

Conclusions:

• Rosuvastatin exhibits superior LDL cholesterol-lowering effectiveness compared to currently available statins.
• This new statin offers a promising option for achieving more aggressive LDL cholesterol reduction and potentially improving management of atherosclerotic disease burden.